Feasibility Study to Assess the Safety and Functionality of the GluSense-LTone 2e3 Continuous Glucose Monitor in Diabetic Patients
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- Evaluate capability to follow glucose concentration changes over 15 consecutive days
研究概览
简要总结
Currently marketed CGM sensors have an approved functional lifetime of up to 1 week. Pre-clinical studies have demonstrated that GluSense-LTone 2e3 sensors may be used to accurately monitor glucose levels for 30 days. The purpose of this study is to assess the safety and functionality of the device in human patients for consecutive 15 days.
GluSense-LTone 2e3 as long term CGM, will require less sensor replacements and calibration, meaning less patient interventions, and is therefore will be much more user friendly. Moreover, GluSense-LTone 2e3 shows potentially increased accuracy, especially in the critically important hypoglycemic range, meaning that better management of patient's condition may be attained.
详细描述
GluSense-LTone 2e3 is a continuous glucose monitoring (CGM) system. It is a semi-invasive, optical fiber-based device with a lifetime of up to one month. The purpose of this study is to assess the safety, accuracy, calibration requirements and effective lifetime of the device.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must meet all of the following inclusion criteria to be eligible for participation in this study:
- •Male or female patients between 18 and 50 years of age
- •Patients with type 1 diabetes mellitus.
- •The ability to read, understand and sign an informed consent form. Written consent must be obtained prior to initiation of study procedures
排除标准
- •Patients who meet any of the following exclusion criteria are not to be enrolled in this study:
- •Clinical significant illness that can compromise patient's health during study such as:
- •Significant current heart disease
- •Significant Liver or kidney disease
- •HIV infection
- •Hepatitis B or Hepatitis C infection
- •Malignancy
- •Major allergic skin disease including plaster allergies
- •Significant allergic disorders
- •Current or recent significant skin conditions (e.g. eczema, psoriasis,).
- •Presence of skin markings/ abnormalities around implantation site that will interfere with the skin assessment e.g. tattoos, piercings, birthmark, sunburn
- •Current alcohol or substance use judged by the IP to potentially interfere with patient study compliance.
- •Routine administration of Steroid based medications.
- •Patients currently taking part in any other clinical trial using an investigational product within the last 3 months
结局指标
主要结局
Evaluate capability to follow glucose concentration changes over 15 consecutive days
时间窗: 3 weeks
次要结局
未报告次要终点